ScholarIQanswers from OpenAlex

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

PaperCitations, authors & open-access status

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial have?

ScholarIQcitation count

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial has 163 citations in the OpenAlex counts ScholarIQ stores.

When was Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial published?

ScholarIQyear

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial has 2020 year in the ScholarIQ index.

What is the open-access status of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial?

ScholarIQoa status

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial has green oa status in the ScholarIQ index.

What is the DOI of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial?

ScholarIQdoi

The DOI for Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial is on the source record.

What is the PMID of Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial?

ScholarIQpmid

The PMID for Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial is on the source record.

What is the OpenAlex record for Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial?

ScholarIQopenalex

The OpenAlex for Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial